Show simple item record

Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.

dc.contributor.authorNOEL-BARON, F
dc.contributor.authorÖzgüroglu, Mustafa
dc.contributor.authorFAN, J
dc.contributor.authorLOUVEAU, AL
dc.contributor.authorBURRIS, H
dc.contributor.authorJERUSALEM, G
dc.contributor.authorde, Boer
dc.contributor.authorHURVITZ, S
dc.contributor.authorYARDLEY, DA
dc.contributor.authorKOVALENKO, E
dc.contributor.authorEJLERTSEN, B
dc.contributor.authorBLAU, S
dc.contributor.authorLANDHERR, L
dc.contributor.authorEWERTZ, M
dc.contributor.authorTARAN, T
dc.date.accessioned2021-03-03T20:25:16Z
dc.date.available2021-03-03T20:25:16Z
dc.identifier.citationJERUSALEM G., de B., HURVITZ S., YARDLEY D., KOVALENKO E., EJLERTSEN B., BLAU S., Özgüroglu M., LANDHERR L., EWERTZ M., et al., "Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.", JAMA oncology, cilt.4, ss.1367-1374, 2018
dc.identifier.issn2374-2437
dc.identifier.othervv_1032021
dc.identifier.otherav_59c81914-addd-4162-abf0-4a9a732bad6a
dc.identifier.urihttp://hdl.handle.net/20.500.12627/63154
dc.identifier.urihttps://doi.org/10.1001/jamaoncol.2018.2262
dc.language.isoeng
dc.titleEverolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.
dc.typeMakale
dc.relation.journalJAMA oncology
dc.contributor.department, ,
dc.identifier.volume4
dc.identifier.startpage1367
dc.identifier.endpage1374
dc.contributor.firstauthorID158764


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record